Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 21719098)

1.

Anti-CD3 antibodies for type 1 diabetes: beyond expectations.

Bach JF.

Lancet. 2011 Aug 6;378(9790):459-60. doi: 10.1016/S0140-6736(11)60980-X. Epub 2011 Jun 28. No abstract available.

PMID:
21719098
2.

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators.

Lancet. 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28.

3.

Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies.

Cernea S, Herold KC.

Clin Immunol. 2010 Feb;134(2):121-9. doi: 10.1016/j.clim.2009.09.005.

4.

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA; Immune Tolerance Network ITN007AI Study Group.

Clin Immunol. 2009 Aug;132(2):166-73. doi: 10.1016/j.clim.2009.04.007. Epub 2009 May 14.

5.
6.

[One step towards restoration of self-tolerance in human autoimmune diseases].

Chatenoud L.

Med Sci (Paris). 2007 Feb;23(2):167-71. Review. French.

7.

CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.

Chatenoud L, Waldmann H.

Rev Diabet Stud. 2012 Winter;9(4):372-81. doi: 10.1900/RDS.2012.9.372. Epub 2012 Dec 28. Review.

8.

[Anti-CD3 monoclonal antibodies: a new step towards therapy in new-onset type 1 diabetes].

Chatenoud L.

Med Sci (Paris). 2006 Jan;22(1):5-6. French. No abstract available.

9.

Can we change the course of beta-cell destruction in type 1 diabetes?

Gale EA.

N Engl J Med. 2002 May 30;346(22):1740-2. No abstract available.

PMID:
12037155
10.

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.

Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA.

Diabetes. 2005 Jun;54(6):1763-9.

11.

Heterogeneous CD3 expression levels in differing T cell subsets correlate with the in vivo anti-CD3-mediated T cell modulation.

Valle A, Barbagiovanni G, Jofra T, Stabilini A, Perol L, Baeyens A, Anand S, Cagnard N, Gagliani N, Piaggio E, Battaglia M.

J Immunol. 2015 Mar 1;194(5):2117-27. doi: 10.4049/jimmunol.1401551. Epub 2015 Feb 2.

PMID:
25646305
12.

Anti-CD3 clinical trials in type 1 diabetes mellitus.

Daifotis AG, Koenig S, Chatenoud L, Herold KC.

Clin Immunol. 2013 Dec;149(3):268-78. doi: 10.1016/j.clim.2013.05.001. Epub 2013 May 11. Review.

PMID:
23726024
13.

Type 1 diabetes--does suppressing T cells increase insulin?

Lernmark A.

N Engl J Med. 2005 Jun 23;352(25):2642-4. No abstract available.

PMID:
15972873
14.

Otelixizumab in the treatment of type 1 diabetes mellitus.

Sprangers B, Van der Schueren B, Gillard P, Mathieu C.

Immunotherapy. 2011 Nov;3(11):1303-16. doi: 10.2217/imt.11.123.

PMID:
22053883
15.

[Antibodies instead of insulin?].

Anders S, Kühnemund L, Stauch M, Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2010 Mar;39(2):97-8. doi: 10.1002/pauz.201090017. German. No abstract available.

PMID:
20196056
16.

Retuning the immune system: the future of type 1 diabetes therapy?

Jones D.

Nat Rev Drug Discov. 2009 Aug;8(8):600-1. doi: 10.1038/nrd2956.

PMID:
19644464
17.

Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF.

Ablamunits V, Bisikirska B, Herold KC.

Eur J Immunol. 2010 Oct;40(10):2891-901. doi: 10.1002/eji.201040485.

18.

CD3-specific antibodies: a portal to the treatment of autoimmunity.

Chatenoud L, Bluestone JA.

Nat Rev Immunol. 2007 Aug;7(8):622-32. Epub 2007 Jul 20. Review.

PMID:
17641665
19.

[CD3-specific antibody-induced T-cell apoptosis and apoptotic cell uptake lead to CD3-specific antibody-induced tolerance].

Perruche S, Saas P.

Med Sci (Paris). 2009 Apr;25(4):325-7. doi: 10.1051/medsci/2009254325. French. No abstract available.

20.

Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3.

Mamchak AA, Manenkova Y, Leconet W, Zheng Y, Chan JR, Stokes CL, Shoda LK, von Herrath M, Bresson D.

Diabetes. 2012 Jun;61(6):1490-9. doi: 10.2337/db11-1304. Epub 2012 Feb 23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk